Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7862420 | 1.00 | DRD3 (0.54) | DRD3FYNALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL9776918 | 0.90 | DRD3 (0.61) | DRD3FYNALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL9441640 | 0.82 | DRD3 (0.53) | DRD3DRD2 | |
| SCHEMBL7864930 | 0.82 | DRD3 (0.61) | DRD3FYNDRD2 | |
| SCHEMBL8900096 | 0.82 | DRD3 (0.61) | DRD3FYNDRD2 | |
| SCHEMBL17822689 | 0.82 | DRD3 (0.55) | DRD3FYNALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL7854607 | 0.78 | DRD3 (0.51) | DRD3FYNALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL8694462 | 0.78 | DRD3 (0.58) | DRD3FYNALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL8691897 | 0.78 | DRD3 (0.54) | DRD3FYNALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL8690081 | 0.76 | ALDH1A1 (0.69) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| US-11077072-B2 | Binge behavior regulators | Clearmind Medicine Inc. | 2021-08-03 | — | — | US | disclosed |
| EP-3705469-A1 | BINGE BEHAVIOR REGULATORS | GOLAN, Ezekiel (CA) | 2020-09-09 | — | — | EP | disclosed |
| EP-3230255-B1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (CA) | 2020-03-18 | — | — | EP | disclosed |
| US-10406123-B2 | Binge behavior regulators | CLEARMIND LABS CORP. (CA) | 2019-09-10 | — | — | US | disclosed |
| US-10137096-B2 | Binge behavior regulators | CLEARMIND LABS CORP. (CA) | 2018-11-27 | — | — | US | disclosed |
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2018-03-29 | — | — | US | disclosed |
| US-20170360067-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | CLEARMIND LABS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-5708018-A | 2-aminoindans as selective dopamine D3 ligands | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0712387-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD3 131/4885FYN 4855/4885ALDH1A1 847/4885 |
| US-10137096-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885FYN 4855/4885ALDH1A1 847/4885 |
| US-11077072-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885FYN 4855/4885ALDH1A1 847/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | DRD3 431/4885FYN 3559/4885ALDH1A1 34/4885 |
| US-10406123-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885FYN 4855/4885ALDH1A1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.